Mona Amini‐Adlé

600 total citations
30 papers, 275 citations indexed

About

Mona Amini‐Adlé is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Mona Amini‐Adlé has authored 30 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Epidemiology. Recurrent topics in Mona Amini‐Adlé's work include Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (5 papers) and Melanoma and MAPK Pathways (5 papers). Mona Amini‐Adlé is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (5 papers) and Melanoma and MAPK Pathways (5 papers). Mona Amini‐Adlé collaborates with scholars based in France, United States and Sweden. Mona Amini‐Adlé's co-authors include L. Thomas, Stéphane Dalle, Philip Robinson, Delphine Maucort‐Boulch, B. Balme, P. Sève, Marie Perier‐Muzet, Laurent Kodjikian, Claire Falandry and Amélie Boespflug and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and European Journal of Cancer.

In The Last Decade

Mona Amini‐Adlé

23 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mona Amini‐Adlé France 9 178 81 48 42 41 30 275
Lucie Heinzerling Germany 8 146 0.8× 70 0.9× 51 1.1× 10 0.2× 8 0.2× 22 210
Stefan Schliep Germany 10 103 0.6× 82 1.0× 92 1.9× 4 0.1× 30 0.7× 27 251
Kristina Buder‐Bakhaya Germany 7 256 1.4× 77 1.0× 106 2.2× 7 0.2× 6 0.1× 10 320
Tanuj Banker United States 4 107 0.6× 133 1.6× 16 0.3× 44 1.0× 9 0.2× 7 316
Muhammad Adnan Khattak Australia 9 185 1.0× 77 1.0× 101 2.1× 42 1.0× 6 0.1× 33 264
Deepal Wakade Australia 7 307 1.7× 119 1.5× 64 1.3× 4 0.1× 94 2.3× 8 409
Naima Benannoune France 2 441 2.5× 127 1.6× 159 3.3× 3 0.1× 49 1.2× 6 517
H. Cazenave France 3 443 2.5× 127 1.6× 160 3.3× 3 0.1× 51 1.2× 4 520
P. Flynn United States 6 82 0.5× 178 2.2× 74 1.5× 4 0.1× 11 0.3× 12 320
Melissa Langer Germany 9 287 1.6× 51 0.6× 26 0.5× 6 0.1× 13 0.3× 10 408

Countries citing papers authored by Mona Amini‐Adlé

Since Specialization
Citations

This map shows the geographic impact of Mona Amini‐Adlé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona Amini‐Adlé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona Amini‐Adlé more than expected).

Fields of papers citing papers by Mona Amini‐Adlé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mona Amini‐Adlé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona Amini‐Adlé. The network helps show where Mona Amini‐Adlé may publish in the future.

Co-authorship network of co-authors of Mona Amini‐Adlé

This figure shows the co-authorship network connecting the top 25 collaborators of Mona Amini‐Adlé. A scholar is included among the top collaborators of Mona Amini‐Adlé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona Amini‐Adlé. Mona Amini‐Adlé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chabaud, Sylvie, Aude Fléchon, Helen Boyle, et al.. (2025). Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin. European Journal of Cancer. 222. 115427–115427. 1 indexed citations
2.
Heudel, Pierre-Étienne, et al.. (2025). The impact of tele-expertise in oncology: current state and future perspectives. Frontiers in Digital Health. 7. 1552182–1552182.
3.
Amini‐Adlé, Mona, et al.. (2024). Zanubrutinib-associated ecchymotic lesions. The Lancet Haematology. 11(9). e708–e708.
4.
Dalle, Stéphane, Estelle Verronèse, Céline Rodriguez, et al.. (2024). Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients. OncoImmunology. 13(1). 2372118–2372118. 1 indexed citations
5.
6.
Assaad, Souad, et al.. (2024). Gastric signet-ring cell adenocarcinoma masquerading as sarcoidosis. The Lancet Oncology. 25(4). e173–e173.
7.
Wolkenstein, P., et al.. (2023). French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study. European Journal of Medical Genetics. 66(5). 104734–104734. 1 indexed citations
8.
Dalle, Stéphane, Émilie Varey, A. Dupuy, et al.. (2022). Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database. European Journal of Dermatology. 32(6). 691–697. 2 indexed citations
9.
Piperno, Muriel, Marie Kostine, Denis Maillet, et al.. (2021). Effets secondaires rhumatologiques immuno-induits par les inhibiteurs de points de contrôle de la réponse immunitaire. Bulletin du Cancer. 108(6). 643–653. 2 indexed citations
10.
Combemale, P., Laurène Sonzogni, Clément Devic, et al.. (2021). Individual Response to Radiation of Individuals with Neurofibromatosis Type I: Role of the ATM Protein and Influence of Statins and Bisphosphonates. Molecular Neurobiology. 59(1). 556–573. 18 indexed citations
11.
Vasseur, Damien, Mona Amini‐Adlé, L. Thomas, et al.. (2019). Concomitant GNA11 and SF3B1 mutations in two cases of melanoma associated with blue naevus. Clinical and Experimental Dermatology. 45(1). 123–126. 1 indexed citations
12.
Amini‐Adlé, Mona & Stéphane Dalle. (2018). Pelade sous ipilimumab. Annales de Dermatologie et de Vénéréologie. 145(6-7). 465–466. 3 indexed citations
13.
Amini‐Adlé, Mona, B. Balme, & Stéphane Dalle. (2018). Maladie de Grover sous anti PD-1 pour mélanome métastatique. Annales de Dermatologie et de Vénéréologie. 145(12). 802–803.
14.
Amini‐Adlé, Mona, et al.. (2018). Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma. BMC Cancer. 18(1). 705–705. 17 indexed citations
15.
Amini‐Adlé, Mona, B. Balme, M. Locatelli-Sanchez, P.-J. Souquet, & Stéphane Dalle. (2018). Éruption lichénoïde cutanéo-muqueuse sous anti-PD-1. Annales de Dermatologie et de Vénéréologie. 145(11). 725–727.
16.
Amini‐Adlé, Mona & Stéphane Dalle. (2018). Vitiligo sous inhibiteur de checkpoint. Annales de Dermatologie et de Vénéréologie. 145(10). 633–635. 1 indexed citations
17.
Amini‐Adlé, Mona, et al.. (2017). Vogt-Koyanagi-Harada–like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma. Journal of Immunotherapy. 40(2). 77–82. 54 indexed citations
18.
Villani, A., et al.. (2013). Linear Atrophoderma of Moulin: Report of 4 Cases and 20th Anniversary Case Review. Dermatology. 227(1). 5–9. 8 indexed citations
19.
Amini‐Adlé, Mona, et al.. (2012). Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?. Clinical Rheumatology. 32(2). 277–280. 9 indexed citations
20.
Amini‐Adlé, Mona, et al.. (2006). Scleromyxedema: Successful Treatment with Thalidomide in Two Patients. Dermatology. 214(1). 58–60. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucie Heinzerling Breakdown of academic impact, for papers by Stefan Schliep Breakdown of academic impact, for papers by Kristina Buder‐Bakhaya Breakdown of academic impact, for papers by Tanuj Banker Breakdown of academic impact, for papers by Muhammad Adnan Khattak Breakdown of academic impact, for papers by Deepal Wakade Breakdown of academic impact, for papers by Naima Benannoune Breakdown of academic impact, for papers by H. Cazenave Breakdown of academic impact, for papers by P. Flynn Breakdown of academic impact, for papers by Melissa Langer
Rankless by CCL
2026